Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan最新文献_第8页

[Evaluation of Pharmacist Interventions to Prevent Acute Kidney Injury Associated with the Combination of Piperacillin/Tazobactam and Vancomycin]. [药师干预预防哌拉西林/他唑巴坦与万古霉素联用所致急性肾损伤的评价]。

IF 0.4 4区医学

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan Pub Date : 2026-01-01 DOI: 10.1248/yakushi.25-00011

Nobuaki Sampa, Kengo Ohashi, Yasutaka Shinoda, Tomoko Matsuoka, Eiseki Usami

{"title":"[Evaluation of Pharmacist Interventions to Prevent Acute Kidney Injury Associated with the Combination of Piperacillin/Tazobactam and Vancomycin].","authors":"Nobuaki Sampa, Kengo Ohashi, Yasutaka Shinoda, Tomoko Matsuoka, Eiseki Usami","doi":"10.1248/yakushi.25-00011","DOIUrl":"10.1248/yakushi.25-00011","url":null,"abstract":"Piperacillin/tazobactam (PIPC/TAZ) and vancomycin (VCM) are frequently used in combination (PTV) to manage severe healthcare-associated infections, but are also associated with an increased risk of acute kidney injury (AKI). In 2019, Ogaki Municipal Hospital implemented pharmacist-led interventions aimed at reducing PTV use and mitigating AKI. This study evaluated the impact of these interventions on antibiotic safety and patient outcomes. This retrospective study included hospitalized patients treated with PTV between January 2010 and December 2023. Details of these pharmacist interventions were reviewed retrospectively. Patients were categorized into pre- and post-intervention periods. The primary outcomes reported were the duration of PTV therapy and the incidence of AKI. Multivariable regression analyses were performed to evaluate the association between the intervention, therapy duration, and AKI incidence. Mediation analysis was conducted to assess whether the reduction in PTV duration mediated the effect of the intervention on AKI incidence. As a result, AKI incidence decreased from 19.8% in the pre-intervention period to 7.7% in the post-intervention period (p=0.038). In the PTV cohort, multivariable models showed lower AKI risk in the post period [adjusted odds ratio (OR) 0.283; 95% confidence interval (CI) 0.086 to 0.803; p=0.024] and a shorter PTV duration (β=-2.011 d; 95% CI -3.459 to -0.563; p=0.007). In mediation analysis, the shortening of PTV duration partially mediated the AKI reduction (ACME p=0.016). In conclusion, pharmacist-led interventions effectively reduced PTV duration leading to a decrease in AKI incidence, highlighting the critical role of pharmacists in promoting antimicrobial stewardship and improving patient outcomes.","PeriodicalId":23810,"journal":{"name":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","volume":"146 2","pages":"131-139"},"PeriodicalIF":0.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146100839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Structural Analysis Using Cryo-electron Microscopy for Protein-based Drug Design]. [用低温电子显微镜分析蛋白质药物设计的结构]。

IF 0.4 4区医学

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan Pub Date : 2026-01-01 DOI: 10.1248/yakushi.25-00183-3

Jun-Ichi Kishikawa

{"title":"[Structural Analysis Using Cryo-electron Microscopy for Protein-based Drug Design].","authors":"Jun-Ichi Kishikawa","doi":"10.1248/yakushi.25-00183-3","DOIUrl":"https://doi.org/10.1248/yakushi.25-00183-3","url":null,"abstract":"Structure-based drug design (SBDD) plays a crucial role in modern drug discovery. SBDD is a methodology that utilizes the three-dimensional (3D) structural information of a target protein to computationally search for compounds that bind to it and/or to optimize the binding of known compounds. This article provides an overview of recent advances in SBDD. Furthermore, we introduce 2 case studies conducted by the authors using single-particle analysis via Cryo-electron microscopy (Cryo-EM), a powerful technique for obtaining protein structures. The first example is the sodium ion (Na+)-translocating NADH-quinone oxidoreductase derived from Vibrio cholerae. This enzyme is suggested to undergo large conformational changes during the reaction cycle. By performing classification in single-particle analysis, we successfully captured a partial view of these conformational dynamics. The second example involves the angiotensin-converting enzyme 2 (ACE2) decoy, which binds to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein and inhibits infection. Focusing on ACE2, which is critical for SARS-CoV-2 infection, an ACE2 decoy was developed to achieve higher binding affinity than the wild-type ACE2. We successfully elucidated how this ACE2 decoy binds to the spike protein.","PeriodicalId":23810,"journal":{"name":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","volume":"146 7","pages":"631-639"},"PeriodicalIF":0.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148370134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Pharmacists as Gatekeepers for Overdose and Suicide Prevention: Providing a Good Background on the Current Situation and Evidence]. [药剂师作为过量用药和自杀预防的看门人：提供良好的现状背景和证据]。

IF 0.2 4区医学

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan Pub Date : 2026-01-01 DOI: 10.1248/yakushi.25-00163-F

Kazuki Nagashima

引用次数: 0

Concerns and Consultation Needs for Hospital and Community Pharmacists at Metastatic or Recurrent Cancer Diagnosis: A Web-Based Survey in Japan. 日本医院和社区药剂师在转移性或复发性癌症诊断中的关注点和咨询需求：一项基于网络的调查

IF 0.4 4区医学

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan Pub Date : 2026-01-01 DOI: 10.1248/yakushi.26-00011

Tomofumi Watanabe, Atsunobu Sagara, Tomoya Abe, Masato Komuro, Hiroyuki Terakado

{"title":"Concerns and Consultation Needs for Hospital and Community Pharmacists at Metastatic or Recurrent Cancer Diagnosis: A Web-Based Survey in Japan.","authors":"Tomofumi Watanabe, Atsunobu Sagara, Tomoya Abe, Masato Komuro, Hiroyuki Terakado","doi":"10.1248/yakushi.26-00011","DOIUrl":"https://doi.org/10.1248/yakushi.26-00011","url":null,"abstract":"Patients diagnosed with metastatic or recurrent cancer experience uncertainty and distress; however, their consultation needs remain insufficiently quantified. We conducted a web survey in Japan (January 23-29, 2025) among adults (≥18 years) with a history of metastatic or recurrent cancer (n=522). Participants selected concerns from 21 items across four domains, and for each endorsed concern, they indicated whether they wished to consult hospital and/or community pharmacists; consultation intention was calculated among those endorsing each item. Hospital-community differences were evaluated using McNemar's test or Mid-P exact test using a significance threshold of p<0.001. The mean age was 58.9±12.9 years; cancers were colorectal (22.2%), breast (18.2%), lung (11.9%), and gastric (11.1%). 88.7% reported at least one concern. The most common concerns were treatment-related side effects (51.0%), anticancer drug mechanism/efficacy (46.9%), treatment costs (42.1%), mental distress (35.1%), and medications used to alleviate cancer- or treatment-related physical discomfort (34.7%). Consultation intention was higher for hospital than community pharmacists for issues including side effects (43.2 vs. 16.2%), mechanism/efficacy (42.9 vs. 18.0%), and symptom-relief medications (48.6 vs. 24.9%). Although concerns regarding medications other than cancer treatment were uncommon (<10% each), consultation intention exceeded 40% when present. These findings indicate that patients with metastatic or recurrent cancer may perceive different consultation roles for hospital and community pharmacists, particularly according to the type of concern. Because these results are based on self-reported consultation intentions rather than actual consultation behavior, they should be regarded as hypothesis-generating and as a basis for future studies on coordinated pharmacist support.","PeriodicalId":23810,"journal":{"name":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","volume":"146 8","pages":"733-740"},"PeriodicalIF":0.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148664167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Perspectives on the Future of Antibody Therapeutic Use for the Prevention and Treatment of Infectious Diseases]. [抗体在传染病防治中的应用前景展望]。

IF 0.4 4区医学

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan Pub Date : 2026-01-01 DOI: 10.1248/yakushi.26-00014

Minoru Tada, Michihiko Aoyama, Akiko Ishii-Watabe

{"title":"[Perspectives on the Future of Antibody Therapeutic Use for the Prevention and Treatment of Infectious Diseases].","authors":"Minoru Tada, Michihiko Aoyama, Akiko Ishii-Watabe","doi":"10.1248/yakushi.26-00014","DOIUrl":"https://doi.org/10.1248/yakushi.26-00014","url":null,"abstract":"Antibodies are endogenous proteins that are involved in humoral immunity. Although various therapeutic monoclonal antibodies (mAbs) targeting cancer and immune diseases have been widely used, the development of mAbs for the treatment of infectious diseases has remained limited. During the coronavirus disease 2019 (COVID-19) pandemic, various mAbs targeting the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were developed, received Emergency Use Authorization (EUA), and were used for treating and preventing COVID-19. As successive SARS-CoV-2 variants emerged and the pandemic spread, mAbs with high target specificity proved less effective against these variants. Consequently, their EUAs were suspended within a short period, highlighting the limitations of antiviral mAbs developed against emerging infectious diseases. Since 2021, guidance documents on mAbs for prevention and treatment of COVID-19 have been issued by the WHO and US FDA, and efforts to prepare a regulatory environment supportive of drug development for future emerging and re-emerging infectious diseases have accelerated. The EMA published a concept paper on development of guidelines for non-clinical and clinical evaluation of mAbs for COVID-19. These trends indicate that the international regulatory landscape for mAbs against infectious diseases is entering a new era. We here provide an overview of the guidance documents issued by regulatory agencies, based on insights obtained from anti-SARS-CoV-2 mAbs during the COVID-19 pandemic. We also discuss the challenges and future prospects for the development of mAbs against infectious diseases, particularly in situations requiring rapid responses during pandemics.","PeriodicalId":23810,"journal":{"name":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","volume":"146 8","pages":"709-721"},"PeriodicalIF":0.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148663859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Development of Drug Discovery Research Based on the Discovery of AlkB Homolog 3 and Establishment of an Academic Drug Discovery Platform]. [基于AlkB同源物发现的药物发现研究进展及药物发现学术平台的建立]。

IF 0.4 4区医学

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan Pub Date : 2026-01-01 DOI: 10.1248/yakushi.26-00016

Kazutake Tsujikawa

{"title":"[Development of Drug Discovery Research Based on the Discovery of AlkB Homolog 3 and Establishment of an Academic Drug Discovery Platform].","authors":"Kazutake Tsujikawa","doi":"10.1248/yakushi.26-00016","DOIUrl":"https://doi.org/10.1248/yakushi.26-00016","url":null,"abstract":"The field of epitranscriptomics, an area of genetics concerning the regulation of gene expression via post-transcriptional RNA modification, is currently attracting substantial research attention. In epitranscriptomics, proteins, collectively termed writers, erasers, and readers, enter into complex interactions that contribute to modifying RNA, thereby maintaining biological homeostasis. However, abnormalities in the expression or function of these proteins can lead to the onset and progression of cancers and neuropsychiatric disorders. Using prostate cancer clinical specimens, I cloned a novel gene, prostate cancer antigen-1 (PCA-1), containing a domain similar to the 2-oxoglutarate, iron(II) [Fe(II)]-dependent oxygenase domain of the Escherichia coli AlkB protein and characterized by enzymatic activity associated with the demethylation of methylated RNA. This was accordingly designated AlkB homolog 3 (ALKBH3). I demonstrate that ALKBH3 is highly expressed in tumor cells in prostate, pancreatic, lung, and other cancers, and its activity is correlated with a poor prognosis. In addition, I developed novel compounds that inhibit the RNA demethylase activity of ALKBH3, thereby providing a basis for developing a first-in-class cancer therapeutic. I also succeeded in cloning the ALKBH8 gene. High ALKBH8 expression was also observed in bladder cancer cells. Furthermore, abnormalities in development and behavior were noted in the generated Alkbh8 knockout mice. On the basis of the experience gained from ALKBH3 drug discovery research, I have established a foundation system for supporting academic drug discovery research. In this review, I describe the pathway followed in integrating the findings of basic pharmaceutical and drug discovery research and further developments.","PeriodicalId":23810,"journal":{"name":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","volume":"146 8","pages":"683-696"},"PeriodicalIF":0.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148663863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Enantioselective Aldol Related-Reactions Catalyzed by Organic Oxides]. 有机氧化物催化的对映选择性醛醇相关反应。

IF 0.4 4区医学

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan Pub Date : 2026-01-01 DOI: 10.1248/yakushi.26-00004

Makoto Nakajima

引用次数: 0

[Prospects for Improving the Efficiency and Accuracy of Pharmaceutical Preparations: The Perspective of Pharmaceutical Companies]. [提高药物制剂效率和准确性的前景：制药公司的视角]。

IF 0.4 4区医学

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan Pub Date : 2026-01-01 DOI: 10.1248/yakushi.25-00176-2

Masahiko Kikuchi

{"title":"[Prospects for Improving the Efficiency and Accuracy of Pharmaceutical Preparations: The Perspective of Pharmaceutical Companies].","authors":"Masahiko Kikuchi","doi":"10.1248/yakushi.25-00176-2","DOIUrl":"10.1248/yakushi.25-00176-2","url":null,"abstract":"There are approximately 60000 pharmacies in Japan. Effective utilization of this resource is a critical national public health issue. With the advent of work style reforms for physicians, pharmacists have a substantial scope to undertake initiatives to improve health literacy. However, if this is simply an extension of the current operations of pharmacies, significant added value cannot be expected. Instead, it is important to envision a future in which pharmacies function as community health stations, contributing to the health literacy of large numbers of people. To ensure that pharmacists have the necessary interpersonal resources, the government has announced policies aimed at streamlining dispensing operations, including outsourcing some of the preparation work involved in dispensing operations, introducing dispensing equipment, dispensing prescription-packaged medicines, and having non-pharmacists assist and support dispensing operations under pharmacist supervision. Considering the near-future vision of pharmacies and pharmacists from a backcasting perspective rather than a forecasting perspective is likely to lead to better outcomes in future.","PeriodicalId":23810,"journal":{"name":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","volume":"146 5","pages":"447-451"},"PeriodicalIF":0.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147843519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Regulatory Science Study for Ensuring the Quality of Therapeutic extracellular vesicle（EV） Products Including Exosomes and Promoting Their Development]. [确保包括外泌体在内的治疗性细胞外囊泡（EV）产品质量并促进其发育的调控科学研究]。

IF 0.4 4区医学

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan Pub Date : 2026-01-01 DOI: 10.1248/yakushi.25-00171-5

Akiko Ishii-Watabe, Hirotaka Nishimura, Tomofumi Yamamoto, Noritaka Hashii

{"title":"[Regulatory Science Study for Ensuring the Quality of Therapeutic extracellular vesicle（EV） Products Including Exosomes and Promoting Their Development].","authors":"Akiko Ishii-Watabe, Hirotaka Nishimura, Tomofumi Yamamoto, Noritaka Hashii","doi":"10.1248/yakushi.25-00171-5","DOIUrl":"10.1248/yakushi.25-00171-5","url":null,"abstract":"Therapeutic extracellular vesicle (EV) products, including those containing exosomes (hereinafter referred to as EV products), are expected to have potential as a new therapeutic modality. Many EV products are currently under development in Japan or other countries; however, there are no guidelines specific to this product category and there is a need for establishing regulatory requirements that supports product development. EVs have an extremely complex structure and show high levels of heterogeneity, and their mechanisms of action remain unclear. Additionally, because therapeutic EV products are often manufactured using cells, and it is difficult to sufficiently remove product- or process- related impurities during the purification process, thus posing challenges for impurity control. To ensure the quality of EV products, it is necessary to conduct sufficient characterization of EV products and to identify critical quality attributes that require control to ensure efficacy and safety. Thus, establishing a strategy for controlling the critical quality attributes within the intended limits, ranges, and distributions is key. Furthermore, it is important to set specifications to confirm that EV products of the intended quality have been obtained. This article describes the current state of research on establishing characterization methods for EV products, and recent topics related to quality issues that need to be considered for the development of therapeutic EV products.","PeriodicalId":23810,"journal":{"name":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","volume":"146 5","pages":"433-440"},"PeriodicalIF":0.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147843451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[DDS Research Aimed at Optimizing Gene and Cell Therapies]. [DDS研究旨在优化基因和细胞疗法]。

IF 0.4 4区医学

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan Pub Date : 2026-01-01 DOI: 10.1248/yakushi.25-00177

Shinsaku Nakagawa

{"title":"[DDS Research Aimed at Optimizing Gene and Cell Therapies].","authors":"Shinsaku Nakagawa","doi":"10.1248/yakushi.25-00177","DOIUrl":"10.1248/yakushi.25-00177","url":null,"abstract":"My research has focused on optimizing drug delivery system (DDS) related gene and cell therapies. In my gene therapy research, I first developed a polyethylene glycol (PEG)-conjugated adenovirus vector (PEG-Ad) to allow modulation of adenovirus pharmacokinetics and achieve tumor targeting. Evaluating correlations between PEG-Ad blood retention, tumor tissue delivery, liver accumulation, and gene expression is an important step toward creating tumor-targeting PEG-Ad, demonstrating that a 90% PEGylation rate optimally reduced liver accumulation and improved tumor targeting via enhanced permeability and retention. To enhance tumor targeting specificity, we designed Cys-Gly-Lys-Arg-Lys (CGKRK)-PEG-Ad, in which the tumor-targeting peptide CGKRK was attached to the end of the PEG chain. Although CGKRK-PEG-Ad exhibited similarly reduced liver accumulation to that of PEG-Ad, its tumor delivery was higher than that of PEG-Ad, demonstrating its potent therapeutic efficacy against metastatic tumors. Next, I worked to optimize tumor immunotherapy by controlling immune cells in vivo dynamics. In this study, cytokines were used to activate antitumor immune cells, and chemokines were used to induce intratumoral infiltration by antitumor immune cells. While intratumoral administration of Arg-Gly-Asp (RGD)-Ad-C-C motif chemokine ligand 27 (CCL27) alone did not produce an antitumor effect against OV-HM tumors; however, co-administration with RGD-Ad-interleukin-12 (IL-12) demonstrated a stronger antitumor effect than administration of RGD-Ad-IL-12 alone. Infiltration of cluster of differentiation 3 (CD3)- and perforin-positive cells into tumor tissues was increased by combined administration of RGD-Ad-CCL27 and RGD-Ad-IL-12 compared with administration of RGD-Ad-IL-12 alone. These results demonstrate the importance of controlling the in vivo dynamics of antitumor immune cells.","PeriodicalId":23810,"journal":{"name":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","volume":"146 4","pages":"319-331"},"PeriodicalIF":0.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147595093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0